32 completed, 20 unknown, 7 terminated, 2 recruiting. 20 Phase 4, 18 Phase 2, 11 Phase 3, 7 Not applicable, 5 Phase 1.
Follow Baraclude: new trials by email Literature Review of Baraclude trials Research Report on Baraclude
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of ZM-H1505R in Combination With ETV Compared With ETV Monotherapy in Patients With CHB ZM-H1505R, ZM-H1505R placebo, Baraclude - Hepatitis B, Chronic | Phase 2 | Unknown | Shanghai Zhimeng Biopharma, Inc. | 90 | 2022-11-11 | 2023-05-08 |
| A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B APG-1387, Entecavir 0.5 mg - Hepatitis B, Chronic Hep B | Phase 2 | Unknown | Ascentage Pharma Group Inc. | 122 | 2020-06-03 | 2021-08-26 |
| Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors Best Practice, Entecavir, Tenofovir Alafenamide - Hepatitis B Infection, Malignant Solid Neoplasm | Phase 3 | Terminated | SWOG Cancer Research Network | 4 | 2020-01-17 | 2024-05-20 |
| Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B Tenofovir alafenamide, Entecavir - Hepatitis B, Viral Hepatitis | Phase 4 | Recruiting | Taichung Veterans General Hospital | 140 | 2019-08-19 | 2026-05-14 |
| Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide - Hepatitis B, Acute-On-Chronic Liver Failure | Not applicable | Recruiting | Third Affiliated Hospital, Sun Yat-Sen University | 150 | 2019-02-21 | 2024-11-29 |
| Three Types of Nucleotide/Nucleoside Analogues Therapy in Patients With Chronic Hepatitis b Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide - Chronic Hepatitis b | Not applicable | Unknown | Third Affiliated Hospital, Sun Yat-Sen University | 300 | 2019-01-01 | 2019-12-17 |
| Three Types of Nucleotide/Nucleoside Analogues Therapy in Patients With Hepatitis b Virus Related Compensated Cirrhosis Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir alafenamide - Hepatitis B, Compensated Cirrhosis | Not applicable | Unknown | Third Affiliated Hospital, Sun Yat-Sen University | 150 | 2019-01-01 | 2019-12-12 |
| A Study to Provide a Better Understanding of Baraclude's Pharmacokinetic Properties in a Real World Clinical Setting Baraclude - Hepatitis B Virus | Phase 1 | Completed | Bristol-Myers Squibb | 6 | 2017-05-16 | 2023-11-18 |
| Tacrolimus Combined With Entecavir on HBV Associated Glomerulonephritis(HBV-GN) Tacrolimus &entecavir, placebo & entecavir - Hepatitis B Virus Associated Nephrotic Syndrome | Phase 4 | Unknown | Guangdong Provincial People's Hospital | 112 | 2017-02-01 | 2017-02-24 |
| Peginterferon Alfa-2b Treatment in HBeAg(+) Chronic Hepatitis b Patients Based on Interferon Gene Mutation and Receptor Detection Entecavir or Tenofovir, Peginterferon Alfa-2B - Chronic Hepatitis b | Phase 4 | Unknown | Third Affiliated Hospital, Sun Yat-Sen University | 100 | 2016-01-01 | 2016-11-25 |
| Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV) ARC-520, entecavir, pegylated interferon alpha 2a - Hepatitis B, Hepatitis D | Phase 2 | Terminated | Arrowhead Pharmaceuticals | 79 | 2015-12-01 | 2026-01-13 |
| A Clinical Trial on Hepatitis B Vaccine Activated-Dendritic Cells Combined With Anti-HBV Drugs in CHB HPDC-T cells & Entecavir, Entecavir, HPDC-T cells & IFN-a-2a - Chronic Hepatitis B | Phase 1 / Phase 2 | Unknown | Third Affiliated Hospital, Sun Yat-Sen University | 450 | 2015-11-01 | 2015-11-26 |
| Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus ARC-520, Placebo, Entecavir - Chronic Hepatitis B | Phase 2 | Terminated | Arrowhead Pharmaceuticals | 4 | 2015-08-01 | 2025-11-03 |
| Study to Evaluate the Non-inferiority of Cavir in HBeAg(+)Chronic Hepatitis B Patients Treated With Baraclude Cavir, Baraclude - Chronic Hepatitis B | Phase 4 | Unknown | Hanmi Pharmaceutical Company Limited | 134 | 2015-01-01 | 2015-08-14 |
| A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection ARC-520, Placebo, entecavir - Hepatitis B, Chronic | Phase 2 | Terminated | Arrowhead Pharmaceuticals | 58 | 2014-03-01 | 2026-01-13 |
| Entecavir for Biological Agents Associated HBV Reactivation in Inflammatory Arthritis Patients Entecavir - Rheumatoid Arthritis, Hepatitis B Reactivation | Phase 4 | Unknown | Taipei Veterans General Hospital, Taiwan | 115 | 2013-09-10 | 2019-03-13 |
| Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL Entecavir, Lamivudine - Non-Hodgkin Lymphoma, Hepatitis B Reactivation | Phase 2 | Unknown | Fudan University | 82 | 2013-02-01 | 2013-08-02 |
| Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma Entecavir prophylaxis, Observation arm - Hepatitis B | Phase 4 | Unknown | Peking University | 190 | 2013-01-01 | 2017-01-10 |
| Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy Entecavir prophylaxis - Hepatitis B | Phase 4 | Unknown | Peking University | 80 | 2013-01-01 | 2017-01-10 |
| Tubular Function in Asian-American Patients Receiving TDF or ETV for HBV Treatment Tenofovir Disoproxil Fumarate, Entecavir - Hepatitis B | Terminated | New Discovery LLC | 48 | 2012-10-01 | 2017-09-06 |
Showing 20 of 63. Sign in to see all of them.
Hepatitis B, Chronic (36) · Hepatitis B (28) · Lymphoma (3) · Chronic Disease (2) · Hepatitis (2) · Lymphoma, Non-Hodgkin (2) · Acute-On-Chronic Liver Failure (1) · Arthritis, Rheumatoid (1) · Carcinoma, Hepatocellular (1) · Fibrosis (1) · Glomerulonephritis, Membranous (1) · Hepatitis D (1) · Liver Cirrhosis (1) · Liver Diseases (1)
Bristol-Myers Squibb (22) · Third Affiliated Hospital, Sun Yat-Sen University (5) · Arrowhead Pharmaceuticals (3) · Asan Medical Center (3) · Peking University (2) · Taipei Veterans General Hospital, Taiwan (2) · Ascentage Pharma Group Inc. (1) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (1) · Beijing 302 Hospital (1) · Beijing Friendship Hospital (1) · Bukwang Pharmaceutical (1) · Chongqing Jiachen Biotechnology Ltd. (1) · Chulalongkorn University (1) · Dynavax Technologies Corporation (1) · Foundation for Liver Research (1)
China (21) · United States (16) · South Korea (15) · Taiwan (13) · Canada (9) · Poland (9) · Brazil (7) · Italy (7) · Turkey (Türkiye) (7) · France (6) · Germany (6) · Singapore (6) · Thailand (6) · Argentina (5) · Australia (5)
Liang Peng, Doctor (4) · Jun Zhu (2) · Young-Suk Lim, M.D., Ph.D. (2) · Bruce Given, MD (1) · Calvin Q Pan, M.D. (1) · Dong Ji Jia, Doctor (1) · Fu-Sheng Wang, Professor (1) · Heiner Wedemeyer, MD (1) · Huy N Trinh, M.D. (1) · James Fung, MBChB (1) · Jessica P Hwang (1) · Jian Shi, MD (1) · John Flaherty, PharmD (1)
PMID 30876946, PMID 10613747, PMID 15470215, PMID 15565615, PMID 15985009, PMID 16164651, PMID 16525138, PMID 16879891, PMID 17377504, PMID 19052126, PMID 20220333, PMID 2023605, PMID 21254162, PMID 2142748, PMID 21677438, PMID 22233350, PMID 22371643, PMID 22643350, PMID 22668640, PMID 23150796, PMID 23449768, PMID 23689577, PMID 23732715, PMID 23775967, PMID 23876210, PMID 24189358, PMID 24375637, PMID 25168842, PMID 25348661, PMID 25476749, PMID 25596179, PMID 25800784, PMID 26223345, PMID 26389937, PMID 26739688, PMID 28103819, PMID 28404091, PMID 28404092, PMID 28427875, PMID 28611778, PMID 29405329, PMID 29696665, PMID 30689258, PMID 31306800, PMID 32460460, PMID 33447520, PMID 33460002, PMID 33712437, PMID 35599306, PMID 35672893
2008 (1), 2009 (1), 2015 (1), UG1CA189974 (1)